Inventor
RECH JASON C
US17 patents
⚠️ This page may combine multiple inventors who share the name “RECH JASON C”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
JANSSEN PHARMACEUTICA NV
14 patentsUS10071988B2Sep 11, 2018
Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
JANSSEN PHARMACEUTICA NV17 citations93
US9963447B2May 8, 2018
Substituted 4-azaindoles and their use as GluN2B receptor modulators
JANSSEN PHARMACEUTICA NV17 citations93
US10112937B2Oct 30, 2018
P2X7 modulators and methods of use
JANSSEN PHARMACEUTICA NV11 citations92
US10617676B2Apr 14, 2020
Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GluN2B receptor modulators
JANSSEN PHARMACEUTICA NV12 citations85
US10377753B2Aug 13, 2019
Substituted 4-azaindoles and their use as GluN2B receptor modulators
JANSSEN PHARMACEUTICA NV13 citations83
US10233173B2Mar 19, 2019
Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
JANSSEN PHARMACEUTICA NV13 citations83
US9040534B2May 26, 2015
[1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
JANSSEN PHARMACEUTICA NV6 citations83
US11207298B2Dec 28, 2021
Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators
JANSSEN PHARMACEUTICA NV2 citations72
US10766880B2Sep 8, 2020
Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
JANSSEN PHARMACEUTICA NV2 citations72
US11759455B2Sep 19, 2023
Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators
JANSSEN PHARMACEUTICA NV0 citations62
US12338243B2Jun 24, 2025
P2X7 modulators
JANSSEN PHARMACEUTICA NV0 citations52
US10053463B2Aug 21, 2018
Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
JANSSEN PHARMACEUTICA NV0 citations51
US10047092B2Aug 14, 2018
Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
JANSSEN PHARMACEUTICA NV0 citations51
US9440978B2Sep 13, 2016
Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
JANSSEN PHARMACEUTICA NV0 citations51